Patents by Inventor Lance Leopold

Lance Leopold has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMBINATION OF A PD-1 ANTAGONIST AND AN IDO1 INHIBITOR FOR TREATING CANCER
    Publication number: 20190270812
    Abstract: The present disclosure describes combination therapies comprising an antagonist of Programmed Death 1 receptor (PD-1) and a selective inhibitor of indoleamine 2, 3-dioxygenase 1 (IDO1), and the use of the combination therapies for the treat-ment of cancer, and in particular for treating cancers that express PD-L 1.
    Type: Application
    Filed: April 4, 2019
    Publication date: September 5, 2019
    Inventors: Lance LEOPOLD, David KAUFMAN
  • COMBINATION OF A PD-1 ANTAGONIST AND AN IDO1 INHIBITOR FOR TREATING CANCER
    Publication number: 20170037125
    Abstract: The present disclosure describes combination therapies comprising an antagonist of Programmed Death 1 receptor (PD-1) and a selective inhibitor of indoleamine 2, 3-dioxygenase 1 (IDO1), and the use of the combination therapies for the treatment of cancer, and in particular for treating cancers that express PD-L1.
    Type: Application
    Filed: February 3, 2015
    Publication date: February 9, 2017
    Inventors: Lance LEOPOLD, David KAUFMAN
  • SPIRO-OXINDOLE MDM2 ANTAGONISTS
    Publication number: 20140148494
    Abstract: Provided herein are compounds, compositions, and methods in the field of medicinal chemistry. The compounds and compositions provided herein relate to spiro-oxindoles which function as antagonists of the interaction between p53 and MDM2, and their use as therapeutics for the treatment of cancer and other diseases.
    Type: Application
    Filed: January 31, 2014
    Publication date: May 29, 2014
    Applicants: The Regents of the University of Michigan, Sanofi, Ascenta Licensing Corporation
    Inventors: Shaomeng Wang, Yujun Zhao, Wei Sun, Sanjeev Kumar, Lance Leopold, Laurent Debussche, Cedric Barriere, Jean-Christophe Carry, Kwame Amaning
  • SPIRO-OXINDOLE MDM2 ANTAGONISTS
    Publication number: 20120122947
    Abstract: Provided herein are compounds, compositions, and methods in the field of medicinal chemistry. The compounds and compositions provided herein relate to spiro-oxindoles which function as antagonists of the interaction between p53 and MDM2, and their use as therapeutics for the treatment of cancer and other diseases.
    Type: Application
    Filed: November 11, 2011
    Publication date: May 17, 2012
    Applicants: THE REGENTS OF THE UNIVERSITY OF MICHIGAN, SANOFI, ASCENTA THERAPEUTICS, INC.
    Inventors: Shaomeng Wang, Yujun Zhao, Wei Sun, Sanjeev Kumar, Lance Leopold, Laurent Debussche, Cedric Barriere, Jean-Christophe Carry, Kwame Amaning
  • Pulsatile Dosing of Gossypol for Treatment of Disease
    Publication number: 20100189683
    Abstract: This invention relates to pulsatile dose administration of gossypol or pharmaceutical compositions thereof for treating diseases, disorders and conditions responsive to gossypol, inhibiting the activity of anti-apoptotic Bcl-2 family proteins, inducing apoptosis in cells and increasing the sensitivity of cells to inducers of apoptosis.
    Type: Application
    Filed: December 10, 2009
    Publication date: July 29, 2010
    Applicant: Ascenta Therapeutics, Inc.
    Inventors: Jon T. Holmlund, Mel Sorensen, Lance Leopold, Dajun Yang
  • Pulsatile Dosing of Gossypol for Treatment of Disease
    Publication number: 20090175869
    Abstract: This invention relates to pulsatile dose administration of gossypol, a gossypol-related compound or pharmaceutical compositions thereof for treating diseases, disorders and conditions responsive to gossypol or gossypol-related compound, inhibiting the activity of anti-apoptotic Bcl-2 family proteins, inducing apoptosis in cells and increasing the sensitivity of cells to inducers of apoptosis.
    Type: Application
    Filed: December 10, 2008
    Publication date: July 9, 2009
    Applicant: Ascenta Therapeutics, Inc.
    Inventors: Jon T. Holmlund, Mel Sorensen, Lance Leopold, Dajun Yang
  • Pulsatile dosing of gossypol for treatment of disease
    Publication number: 20090010878
    Abstract: This invention relates to pulsatile dose administration of gossypol or pharmaceutical compositions thereof for treating diseases, disorders and conditions responsive to gossypol, inhibiting the activity of anti-apoptotic Bcl-2 family proteins, inducing apoptosis in cells and increasing the sensitivity of cells to inducers of apoptosis.
    Type: Application
    Filed: June 2, 2008
    Publication date: January 8, 2009
    Applicant: Ascenta Therapeutics, Inc.
    Inventors: Jon T. Holmlund, Mel Sorensen, Lance Leopold, Dajun Yang
  • Combination therapy for the treatment of acute leukemia and myelodysplastic syndrome
    Publication number: 20070269430
    Abstract: Methods of treatment and pharmaceutical combinations are provided for the treatment of acute leukemia, such as acute myelogenous leukemia, and myelodysplastic syndrome. The methods of treatment and pharmaceutical combinations employ an anti-CD33 cytotoxic conjugate in combination with at least one compound selected from the group consisting of an anthracycline and a pyrimidine or purine nucleoside analog. Preferred methods of treatment and pharmaceutical combinations employ gemtuzumab ozogamicin, daunorubicin, and cytarabine.
    Type: Application
    Filed: June 11, 2007
    Publication date: November 22, 2007
    Applicant: Wyeth
    Inventors: Jay Feingold, Matthew Sherman, Lance Leopold, Mark Berger